ResMed Inc.

NYSE:RMD Stock Report

Market Cap: US$37.8b

ResMed Valuation

Is RMD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of RMD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: RMD ($245.73) is trading below our estimate of future cash flow value ($278.04)

Significantly Below Future Cash Flow Value: RMD is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RMD?

Key metric: As RMD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RMD. This is calculated by dividing RMD's market cap by their current earnings.
What is RMD's PE Ratio?
PE Ratio24.1x
EarningsUS$1.49b
Market CapUS$37.82b

Price to Earnings Ratio vs Peers

How does RMD's PE Ratio compare to its peers?

The above table shows the PE ratio for RMD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.2x
GEHC GE HealthCare Technologies
17.2x7.93%US$36.1b
EW Edwards Lifesciences
41.8x14.93%US$46.0b
IDXX IDEXX Laboratories
46.5x9.82%US$51.8b
DXCM DexCom
35.2x18.46%US$26.6b
RMD ResMed
24.1x9.00%US$37.8b

Price-To-Earnings vs Peers: RMD is good value based on its Price-To-Earnings Ratio (24.1x) compared to the peer average (35.2x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does RMD's PE Ratio compare vs other companies in the US Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EMBC Embecta
4.2x5.68%US$595.75m
MHUA.F Meihua International Medical Technologies
0.9xn/aUS$8.40m
ARTH.Q Arch Therapeutics
n/an/aUS$4.00
No more companies available in this PE range
RMD 24.1xIndustry Avg. 29.7xNo. of Companies10PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RMD is good value based on its Price-To-Earnings Ratio (24.1x) compared to the US Medical Equipment industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is RMD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RMD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio24.1x
Fair PE Ratio29.7x

Price-To-Earnings vs Fair Ratio: RMD is good value based on its Price-To-Earnings Ratio (24.1x) compared to the estimated Fair Price-To-Earnings Ratio (29.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RMD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$245.73
US$297.47
+21.05%
10.08%US$345.00US$230.00n/a15
Feb ’27US$258.31
US$297.47
+15.16%
10.08%US$345.00US$230.00n/a15
Jan ’27US$240.87
US$291.80
+21.14%
10.04%US$345.00US$225.00n/a15
Dec ’26US$248.38
US$293.47
+18.15%
9.28%US$335.00US$225.00n/a15
Nov ’26US$246.88
US$293.47
+18.87%
9.28%US$335.00US$225.00n/a15
Oct ’26US$270.85
US$293.29
+8.28%
9.50%US$330.00US$215.00n/a14
Sep ’26US$274.51
US$291.86
+6.32%
9.06%US$325.00US$215.00n/a14
Aug ’26US$279.20
US$289.71
+3.77%
8.57%US$325.00US$215.00n/a14
Jul ’26US$256.26
US$264.49
+3.21%
9.12%US$295.00US$200.00n/a15
Jun ’26US$244.79
US$264.49
+8.05%
9.12%US$295.00US$200.00n/a15
May ’26US$236.49
US$263.49
+11.42%
9.26%US$295.00US$200.00n/a15
Apr ’26US$222.30
US$270.09
+21.50%
9.30%US$295.00US$195.00n/a15
Mar ’26US$233.52
US$270.09
+15.66%
9.32%US$295.00US$195.00n/a14
Feb ’26US$236.18
US$269.54
+14.13%
9.31%US$295.00US$195.00US$258.3114
Jan ’26US$228.69
US$256.33
+12.09%
10.16%US$295.00US$190.00US$240.8713
Dec ’25US$249.02
US$253.39
+1.76%
10.08%US$283.00US$190.00US$248.3811
Nov ’25US$244.28
US$253.39
+3.73%
10.08%US$283.00US$190.00US$246.8811
Oct ’25US$238.75
US$240.48
+0.73%
10.94%US$280.00US$180.00US$270.8511
Sep ’25US$245.02
US$232.83
-4.97%
7.79%US$264.00US$200.00US$274.5110
Aug ’25US$214.56
US$222.96
+3.92%
9.53%US$264.00US$180.00US$279.2010
Jul ’25US$186.94
US$220.42
+17.91%
9.86%US$264.00US$180.00US$256.2611
Jun ’25US$206.33
US$216.65
+5.00%
10.28%US$264.00US$180.00US$244.7912
May ’25US$215.01
US$215.05
+0.02%
10.28%US$264.00US$180.00US$236.4913
Apr ’25US$189.32
US$205.67
+8.64%
11.28%US$258.00US$164.00US$222.3013
Mar ’25US$174.61
US$204.98
+17.39%
11.11%US$258.00US$164.00US$233.5213
Feb ’25US$193.66
US$201.32
+3.95%
11.97%US$258.00US$164.00US$236.1812
US$297.47
Fair Value
17.4% undervalued intrinsic discount
15
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/12 17:22
End of Day Share Price 2026/02/12 00:00
Earnings2025/12/31
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ResMed Inc. is covered by 45 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael PolarkBaird
David RescottBaird
Matthew TaylorBarclays